Correlation Between Eliem Therapeutics and Blueprint Medicines
Can any of the company-specific risk be diversified away by investing in both Eliem Therapeutics and Blueprint Medicines at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eliem Therapeutics and Blueprint Medicines into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Eliem Therapeutics and Blueprint Medicines Corp, you can compare the effects of market volatilities on Eliem Therapeutics and Blueprint Medicines and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eliem Therapeutics with a short position of Blueprint Medicines. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eliem Therapeutics and Blueprint Medicines.
Diversification Opportunities for Eliem Therapeutics and Blueprint Medicines
-0.33 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Eliem and Blueprint is -0.33. Overlapping area represents the amount of risk that can be diversified away by holding Eliem Therapeutics and Blueprint Medicines Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Blueprint Medicines Corp and Eliem Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eliem Therapeutics are associated (or correlated) with Blueprint Medicines. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Blueprint Medicines Corp has no effect on the direction of Eliem Therapeutics i.e., Eliem Therapeutics and Blueprint Medicines go up and down completely randomly.
Pair Corralation between Eliem Therapeutics and Blueprint Medicines
Given the investment horizon of 90 days Eliem Therapeutics is expected to under-perform the Blueprint Medicines. In addition to that, Eliem Therapeutics is 1.53 times more volatile than Blueprint Medicines Corp. It trades about -0.32 of its total potential returns per unit of risk. Blueprint Medicines Corp is currently generating about 0.21 per unit of volatility. If you would invest 8,247 in Blueprint Medicines Corp on August 26, 2024 and sell it today you would earn a total of 1,168 from holding Blueprint Medicines Corp or generate 14.16% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 95.45% |
| Values | Daily Returns |
Eliem Therapeutics vs. Blueprint Medicines Corp
Performance |
| Timeline |
| Eliem Therapeutics |
| Blueprint Medicines Corp |
Eliem Therapeutics and Blueprint Medicines Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Eliem Therapeutics and Blueprint Medicines
The main advantage of trading using opposite Eliem Therapeutics and Blueprint Medicines positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eliem Therapeutics position performs unexpectedly, Blueprint Medicines can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will offset losses from the drop in Blueprint Medicines' long position.| Eliem Therapeutics vs. Pmv Pharmaceuticals | Eliem Therapeutics vs. MediciNova | Eliem Therapeutics vs. Pharvaris BV | Eliem Therapeutics vs. PepGen |
| Blueprint Medicines vs. Eliem Therapeutics | Blueprint Medicines vs. HCW Biologics | Blueprint Medicines vs. Scpharmaceuticals | Blueprint Medicines vs. Milestone Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Complementary Tools
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |